These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 25537990)

  • 41. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 42.
    Unterrainer M; Galldiks N; Suchorska B; Kowalew LC; Wenter V; Schmid-Tannwald C; Niyazi M; Bartenstein P; Langen KJ; Albert NL
    J Nucl Med; 2017 Apr; 58(4):584-589. PubMed ID: 27754904
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Assessment of treatment response in patients with glioblastoma using O-(2-18F-fluoroethyl)-L-tyrosine PET in comparison to MRI.
    Galldiks N; Langen KJ; Holy R; Pinkawa M; Stoffels G; Nolte KW; Kaiser HJ; Filss CP; Fink GR; Coenen HH; Eble MJ; Piroth MD
    J Nucl Med; 2012 Jul; 53(7):1048-57. PubMed ID: 22645298
    [TBL] [Abstract][Full Text] [Related]  

  • 44. O-(2-18F-fluoroethyl)-L-tyrosine PET predicts failure of antiangiogenic treatment in patients with recurrent high-grade glioma.
    Hutterer M; Nowosielski M; Putzer D; Waitz D; Tinkhauser G; Kostron H; Muigg A; Virgolini IJ; Staffen W; Trinka E; Gotwald T; Jacobs AH; Stockhammer G
    J Nucl Med; 2011 Jun; 52(6):856-64. PubMed ID: 21622893
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dynamic 18F-FET PET is a powerful imaging biomarker in gadolinium-negative gliomas.
    Kunz M; Albert NL; Unterrainer M; la Fougere C; Egensperger R; Schüller U; Lutz J; Kreth S; Tonn JC; Kreth FW; Thon N
    Neuro Oncol; 2019 Feb; 21(2):274-284. PubMed ID: 29893965
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma.
    Floeth FW; Pauleit D; Sabel M; Stoffels G; Reifenberger G; Riemenschneider MJ; Jansen P; Coenen HH; Steiger HJ; Langen KJ
    J Nucl Med; 2007 Apr; 48(4):519-27. PubMed ID: 17401087
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Static FET-PET and MR Imaging in Anaplastic Gliomas (WHO III).
    Bette S; Peschke P; Kaesmacher J; Delbridge C; Pyka T; Schmidt-Graf F; Zimmer C; Meyer B; Ringel F; Gempt J
    World Neurosurg; 2016 Jul; 91():524-531.e1. PubMed ID: 26947726
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biological tumour volumes of gliomas in early and standard 20-40 min
    Unterrainer M; Winkelmann I; Suchorska B; Giese A; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1242-1249. PubMed ID: 29487977
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dual-time-point O-(2-[(18)F]fluoroethyl)-L-tyrosine PET for grading of cerebral gliomas.
    Lohmann P; Herzog H; Rota Kops E; Stoffels G; Judov N; Filss C; Galldiks N; Tellmann L; Weiss C; Sabel M; Coenen HH; Shah NJ; Langen KJ
    Eur Radiol; 2015 Oct; 25(10):3017-24. PubMed ID: 25813014
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Correlation of (18)F-fluoroethyl tyrosine positron-emission tomography uptake values and histomorphological findings by stereotactic serial biopsy in newly diagnosed brain tumors using a refined software tool.
    Lopez WO; Cordeiro JG; Albicker U; Doostkam S; Nikkhah G; Kirch RD; Trippel M; Reithmeier T
    Onco Targets Ther; 2015; 8():3803-15. PubMed ID: 26719708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Intra-individual comparison of ¹⁸F-FET and ¹⁸F-DOPA in PET imaging of recurrent brain tumors.
    Kratochwil C; Combs SE; Leotta K; Afshar-Oromieh A; Rieken S; Debus J; Haberkorn U; Giesel FL
    Neuro Oncol; 2014 Mar; 16(3):434-40. PubMed ID: 24305717
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.
    Kebir S; Khurshid Z; Gaertner FC; Essler M; Hattingen E; Fimmers R; Scheffler B; Herrlinger U; Bundschuh RA; Glas M
    Oncotarget; 2017 Jan; 8(5):8294-8304. PubMed ID: 28030820
    [TBL] [Abstract][Full Text] [Related]  

  • 53. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
    J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Monitoring of radiochemotherapy in patients with glioblastoma using O-(2-¹⁸Fluoroethyl)-L-tyrosine positron emission tomography: is dynamic imaging helpful?
    Piroth MD; Liebenstund S; Galldiks N; Stoffels G; Shah NJ; Eble MJ; Coenen HH; Langen KJ
    Mol Imaging; 2013 Sep; 12(6):388-95. PubMed ID: 23981784
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Association between small heat shock protein B11 and the prognostic value of MGMT promoter methylation in patients with high-grade glioma.
    Cheng W; Li M; Jiang Y; Zhang C; Cai J; Wang K; Wu A
    J Neurosurg; 2016 Jul; 125(1):7-16. PubMed ID: 26544773
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FET-PET radiomics in recurrent glioblastoma: prognostic value for outcome after re-irradiation?
    Carles M; Popp I; Starke MM; Mix M; Urbach H; Schimek-Jasch T; Eckert F; Niyazi M; Baltas D; Grosu AL
    Radiat Oncol; 2021 Mar; 16(1):46. PubMed ID: 33658069
    [TBL] [Abstract][Full Text] [Related]  

  • 57. 3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients.
    Idema AJ; Hoffmann AL; Boogaarts HD; Troost EG; Wesseling P; Heerschap A; van der Graaf WT; Grotenhuis JA; Oyen WJ
    J Nucl Med; 2012 Dec; 53(12):1904-10. PubMed ID: 23077112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [18F]fluoroethyltyrosine-positron emission tomography-based therapy monitoring after stereotactic iodine-125 brachytherapy in patients with recurrent high-grade glioma.
    Jansen NL; Suchorska B; Schwarz SB; Eigenbrod S; Lutz J; Graute V; Bartenstein P; Belka C; Kreth FW; la Fougère C
    Mol Imaging; 2013 May; 12(3):137-47. PubMed ID: 23490440
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic impact of postoperative, pre-irradiation (18)F-fluoroethyl-l-tyrosine uptake in glioblastoma patients treated with radiochemotherapy.
    Piroth MD; Holy R; Pinkawa M; Stoffels G; Kaiser HJ; Galldiks N; Herzog H; Coenen HH; Eble MJ; Langen KJ
    Radiother Oncol; 2011 May; 99(2):218-24. PubMed ID: 21497925
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The use of O-(2-18F-fluoroethyl)-L-tyrosine PET for treatment management of bevacizumab and irinotecan in patients with recurrent high-grade glioma: a cost-effectiveness analysis.
    Heinzel A; Müller D; Langen KJ; Blaum M; Verburg FA; Mottaghy FM; Galldiks N
    J Nucl Med; 2013 Aug; 54(8):1217-22. PubMed ID: 23785172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.